Gemcitabine
About
Therapy type: Chemotherapy
Therapy strategy: Antimetabolite
Mappings
NCI Thesaurus: Gemcitabine (ncit:C66876)
RxNorm: gemcitabine (rxcui:12574, omop:1314924)
SNOMED: Gemcitabine (sctid:386920008, omop:4305105)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (2) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine, Tremelimumab | |
| FDA (1) | HER2-positive | Invasive Breast Carcinoma | Gemcitabine, Margetuximab | |
| FDA (1) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine, Pembrolizumab | |
| FDA (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Durvalumab, Gemcitabine | |
| FDA (1) HC (1) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Nivolumab |